Last checked at 12 Jun 2008 07:00
Allowance of US Patent on Isobaric Tandem Mass Tags TMT‚® Launch at ASMS
COBHAM, England (June 12, 2008) - Proteome Sciences plc ("Proteome Sciences") is pleased to announce that the USPTO has issued a Notice of Allowance for its US patent application in isobaric mass labelling for its tandem mass tags (TMT‚®) entitled "Mass Labels" Serial No. 10/489/341 (TMT2). The Notice of Allowance completes the final stage of patent examination and represents the form in which the patent will be granted. This follows grants of the corresponding cases in Europe, Australia and Canada. Issued patents are already granted for TMT1 in the USA, Europe and other main jurisdictions.
Thermo Fisher Scientific, Inc. launched a range of TMT‚® products at the ASMS mass spectrometry meeting in Denver, USA last week less than two months after obtaining the exclusive license for isobaric tandem mass tag technology from Proteome Sciences.
The high profile launch started with a well attended user meeting and was accompanied and endorsed by 8 scientific posters/papers presented by Proteome Sciences and a number of global scientific leaders in the field, confirming the utility and performance of TMT/isobaric mass tags across a broad range of different applications. These have been posted onto our website www.proteomics.com.
Commenting on the US Notice of Allowance and the TMT‚® launch. Christopher Pearce, CEO of Proteome Sciences said:
"We are delighted to have received the Notice of Allowance for TMT2 in the US. The patenting process for TMT1 and TMT2 is largely complete in the major jurisdictions and we can look forward to seeing Thermo Fisher exploiting the considerable opportunities from isobaric mass tags to deliver rapid biomarker and assay solutions.
TMT‚® provides fast, flexible and cost effective workflows seamlessly from biomarker discovery, through validation to clinical development and will accelerate the utility and application of biomarkers in drug development and diagnostics to make personalised medicine a reality"
Ends
About Proteome Sciences:
Proteome Sciences plc is a global leader in applied proteomics, using high sensitivity proprietary techniques to detect and characterise differentially expressed proteins in diseases for diagnostic, prognostic and therapeutic applications.
ProteoSHOP‚® provides integrated proteomic services for biomarker discovery, validation and measurement in clinical trials and in vitro diagnostics. Key features include the proprietary isobaric tandem mass tag technology TMT‚® for accurate and reliable biomarker quantification and the ability to rapidly develop highly reproducible quantitative biomarker assays.
The main focus of its research addresses neurological, oncology and cardiovascular conditions and has discovered blood biomarkers in stroke, brain damage, solid organ transplant rejection and Alzheimer's disease. Proteome Sciences is based in Cobham, UK with facilities in London and Frankfurt.
Contact Proteome Sciences plc at www.proteomics.com
Christopher Pearce, Chief Executive Officer
James Malthouse, Finance Director
Dr. Ian Pike, Chief Business Officer
Tel: +44 (0)1932 865065
Adrian Shaw, IKON Associates
Tel: +44 (0)1483 535102 / +44 (0)797 9900733
Matt Baldwin, COAST Communications
Tel: +44 (0)1233 503200
Shaun Dobson, Landsbanki Securities (UK) Limited
Tel: +44 (0) 207 426 9582
vendor